TITLE

Stavudine Once Daily

AUTHOR(S)
Cheer, S.M.; Goa, K.L.
PUB. DATE
December 2002
SOURCE
Drugs;2002, Vol. 62 Issue 18, p2667
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
▴ Stavudine administered once daily is a nucleoside analogue reverse transcriptase inhibitor. ▴ The efficacy (reduction in viral load and increase in CD4+ lymphocyte counts from baseline) of stavudine once daily-containing triple therapy was similar to that of stavudine immediate release (IR)-containing triple therapy in the treatment of antiretroviral-naive patients with HIV infection in two 48-week, randomised, double-blind trials. ▴ In the largest trial (n = 783), 80% of patients receiving stavudine 75 or 100mg once daily in combination with lamivudine 150mg twice daily and efavirenz 600mg once daily, and 75% of patients receiving stavudine IR 30 or 40mg twice daily-containing combination therapy, had HIV RNA levels reduced to below the limit of quantification at 48 weeks (<400 copies/ml; intent-to-treat analysis). These findings are supported by those from the smaller trial in 150 patients. ▴ Stavudine once daily triple therapy was well tolerated, with the incidence of adverse events being similar to that with stavudine IR. Grades 2-4 treatment related adverse events occurring in ≥3% of patients in either group were dizziness, rash, abnormal dream, headache, insomnia, fatigue and peripheral neurological symptoms. ▴ Peripheral neurological symptoms occurred in 3% of patients receiving long-term treatment with stavudine once daily and 6% of patients receiving stavudine IR in a combined analysis.
ACCESSION #
8864597

 

Related Articles

  • Abacavir-Lamivudine-Zidovudine vs Indinavir-Lamivudine-Zidovudine in Antiretroviral-Naive HIV-Infected Adults. Staszewski, Schlomo; Keiser, Philip; Montaner, Julio; Raffi, Francois; Gathe, Joe; Brotas, Vitor; Hicks, Charles; Hammer, Scott M.; Cooper, David; Johnson, Margaret; Tortell, Stephanie; Cutrell, Amy; Thorborn, Daren; Isaacs, Robin; Hetherington, Seth; Steel, Helen; Spreen, William // JAMA: Journal of the American Medical Association;3/7/2001, Vol. 285 Issue 9, p1155 

    Presents a study to evaluate antiretroviral equivalence and safety of an abacavir-lamivudine-zidovudine, a triple nucleoside combination regimen, compared with an indinavir-lamivudine-zidovudine regimen for the treatment of HIV infection. Design and setting; Patients; Interventions; Main...

  • Human Immunodeficiency Virus Rebound after Suppression to<400 Copies/mL during Initial Highly Active Antiretroviral Therapy Regimens, according to Prior Nucleoside Experience and Duration of Suppression. Phillips, Andrew N.; Staszewski, Schlomo; Lampe, Fiona; Youle, Michael S.; Klauke, Stephen; Bickel, Markus; Sabin, Caroline A.; Doerr, Hans Wilhelm; Johnson, Margaret A.; Loveday, Clive; Miller, Veronica // Journal of Infectious Diseases;10/15/2002, Vol. 186 Issue 8, p1086 

    This study evaluated 1433 human immunodeficiency virus (HIV)-infected patients starting highly active antiretroviral therapy (HAART), 409 (28%) of whom had prior nucleoside experience and achieved an HIV load of <400 copies/mL by 24 weeks of therapy. Three hundred seven patients experienced...

  • Immunologic Response to Combination Nucleoside Analogue plus Protease... Borkowsky, William; Stanley, Kenneth; Douglas, Steven D.; Lee, Sophia; Wiznia, Andrew; Pelton, Stephen; Yogev, Ram; McIntosh, Kenneth; Nachman, Sharon // Journal of Infectious Diseases;7/1/2000, Vol. 182 Issue 1, p96 

    Examines the response of 40 immunologic parameters for clinically-stable, protease inhibitor-naive, HIV-infected children when antiretroviral therapy was changed to a dual nucleoside analogue regimen or a protease inhibitor-containing regimen. Measurement by lymphocyte subsets; Three-color flow...

  • Treat HIv-1 Infected with at Least Two Antiretrovirals.  // Kidney;Sep/Oct99, Vol. 8 Issue 5, p203 

    Discusses an abstract of the article, entitled `Effect of hemodialysis and antiretroviral therapy on plasma viral load in HIV-1 infected hemodialysis patients,' by T.S. Ahuja, N. Niaz. A. Velasco and others.

  • VIRACEPT COMBINATIONS STUDIES.  // AIDS Patient Care & STDs;Jun98, Vol. 12 Issue 6, p495 

    Presents information on the fifth Conference on Retroviruses and Opportunistic Infections in Chicago in 1998. Summarization of the results from clinical trials of the drug Viracept; Use of the drug with other protease inhibitors and anti-human immunodeficiency virus (HIV) drugs; Evaluation of...

  • Abacavir Hypersensitivity Reaction. Hewitt, Ross G. // Clinical Infectious Diseases;4/15/2002, Vol. 34 Issue 8, p1137 

    A hypersensitivity reaction occurs in association with initiation of abacavir therapy as part of combination antiretroviral therapy in ∼3.7% of patients. The reaction is possibly the result of a combination of altered drug metabolism and immune dysfunction, which is poorly understood....

  • A Cohort Study of Nevirapine Tolerance in Clinical Practice: French Aquitaine Cohort, 1997--1999. Bonnet, F.; Lawson-Ayayi, S.; Thiébaut, R.; Ramanampamonjy, R.; Lacoste, D.; Bernard, N.; Malvy, D.; Bonarek, M.; Djossou, F.; Beylot, J.; Dabis, F.; Morlat, P. // Clinical Infectious Diseases;11/15/2002, Vol. 35 Issue 10, p1231 

    We performed a retrospective study to evaluate, under routine circumstances, the tolerance and immunovirological changes associated with antiretroviral regimens that contain nevirapine in 137 patients (88% were antiretroviral experienced). During a mean follow-up of 11 months, 33% of patients...

  • Approaching Eradication of Highly Active Antiretroviral Therapy-Persistent Human Immunodeficiency Virus Type 1 Reservoirs with Immune Activation Therapy. Kulkosky, Joseph; Pomerantz, Roger J. // Clinical Infectious Diseases;12/15/2002, Vol. 35 Issue 12, p1520 

    Highly active antiretroviral therapy (HAART) has dramatically altered the human immunodeficiency virus type 1 (HIV-1) pandemic in the developed world. Most patients treated with HAART will maintain clinically undetectable plasma virus loads with concomitant dramatic decreases in mortality and...

  • Immune Reconstitution Cryptococcosis after Initiation of Successful Highly Active Antiretroviral Therapy. Jenny-Avital, Elizabeth R.; Abadi, Maria // Clinical Infectious Diseases;12/15/2002, Vol. 35 Issue 12, p128 

    Five of 10 patients who commenced successful highly active antiretroviral therapy (HAART) for infection with human immunodeficiency virus type 1 (HIV-1) concurrent with or soon after a diagnosis of cryptococcal infection experienced clinical events characterized by sterile inflammation. Two...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics